Anton Kolomeyer, MD PhD

New eflornithine 8 mg label expands dosing from every 4 to 20 weeks, boosting flexibility, insurance support, and outcomes in tough retinal cases.

High-dose aflibercept 8 mg shows faster fluid drying and longer dosing intervals in AMD, DME and RVO, cutting injections without vision loss.

New data show 8 mg aflibercept dries retinal fluid faster and lasts longer, enabling 12–16 week dosing in AMD, DME, and RVO.

Learn why newer anti‑VEGF options extend treatment for wet AMD, DME and RVO, signaling a shift from VEGF-only to multitarget therapy.

Experts weigh vision-first goals in retinal disease, debating dry OCT vs stable fluid, longer anti‑VEGF intervals, and next‑gen durable therapies.

Experts discuss balancing vision, dry retina goals, fluid tolerance, and longer-lasting anti-VEGF options to cut injection burden.

In this episode, “Diagnostic Imaging in Retinal Vascular Disease Management,” the panelists explore how recent innovations in multimodal imaging are transforming the diagnosis and management of retinal vascular diseases, including AMD, diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The expert faculty discuss the growing role of optical coherence tomography (OCT) as the foundational imaging modality in retina clinics and how additional technologies such as fundus autofluorescence, OCT angiography (OCTA), and ultra-widefield imaging are expanding clinicians’ ability to detect and monitor disease activity.

Welcome back to another Ophthalmology Times series. In this episode titled, “Advancing Care Across Retinal Vascular Diseases,” the expert faculty discussed the evolving management of retinal vascular diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The panel reviewed the significant prevalence and treatment burden associated with these chronic retinal conditions, emphasizing how frequently these diseases are encountered in clinical retina practice and the challenges associated with maintaining long-term patient adherence to therapy.